Document:

Exhibit 10.1

 

Amendment

to

Securities Purchase Agreement

 

This Amendment
To Securities Purchase Agreement (this “Amendment”) is entered into as of May 20, 2020, by and between
Medicine Man Technologies, Inc., a Nevada corporation also known as Schwazze (the “Company”) and Dye Capital
Cann Holdings, LLC, a Delaware limited liability company (the “Buyer”). Capitalized terms used but not defined
herein shall have the meanings given them in the Purchase Agreement (as defined below).

 

RECITALS

 

WHEREAS, the
Company and the Buyer previously entered into that certain Securities Purchase Agreement, dated as of June 5, 2019 (as amended,
the “Purchase Agreement”); and

 

WHEREAS, the
Company and the Buyer wish to amend the Purchase Agreement pursuant to this Amendment.

 

AGREEMENT

 

NOW, THEREFORE,
in consideration of the mutual agreements, covenants and considerations contained herein, the receipt and sufficiency of which
are hereby acknowledged, the parties hereto agree as follows:

 

1.               
Amendment to Section 1(a) of the Purchase Agreement. Section 1(a) of the Purchase Agreement is hereby amended
to read in its entirety as follows:

 

“Purchase of Common Shares and
Warrants. Subject to the satisfaction (or waiver) of the conditions set forth in Sections 6 and 7 below with respect to each
Closing, as applicable, at the applicable Closing, the Company shall issue and sell to the Buyer, and the Buyer agrees to purchase
from the Company on each Closing Date (as defined below), on the terms set forth herein, (w) at the Initial Closing (as defined
below), 1,500,000 Common Shares, along with Warrants to acquire up to 1,500,000 Warrant Shares, (x) at the Second Closing (as defined
below), 3,500,000 Common Shares, along with Warrants to acquire up to 3,500,000 Warrant Shares, (y) at the Third Closing (as defined
below), a minimum of 3,000,000 Common Shares and at Buyer’s election, up to a total of 5,500,000 Common Shares, along with
Warrants to acquire up to a corresponding number of Warrant Shares (collectively, the “Third Closing Option Shares”),
and (z) at the Fourth Closing (as defined below), 187,500 Common Shares, along with Warrants to acquire up to 187,500 Warrant Shares
(collectively, the “Fourth Closing Shares”). The date of the initial Closing (the “Initial Closing”)
is the “Initial Closing Date.” The date of the second closing (the “Second Closing”) is the
“Second Closing Date.” The date of the third Closing (the “Third Closing”) is the “Third
Closing Date.” The date of the fourth Closing (the “Fourth Closing”) is the “Fourth Closing
Date.””

 

2.               
Amendment to Section 1(b) of the Purchase Agreement. Section 1(b) of the Purchase Agreement is hereby amended
to read in its entirety as follows:

 

“Closing. The Initial Closing
Date, the Second Closing Date, the Third Closing Date and the Fourth Closing Date (each, a “Closing Date”) shall
be 12:00 p.m., New York City time, on the date hereof (or such other date and time as is mutually agreed to by the Company and
the Buyer) after notification of satisfaction (or waiver) of the conditions to the Closing set forth in Sections 6 and 7 below,
as applicable to the Closing, at the offices of Dentons US LLP, 1221 Avenue of the Americas, New York, NY 10020. The Closings may
also be undertaken remotely by electronic transfer of Closing documentation.”

 

 

 

    	 	1	 

     

    

 

3.               
Addition of Section 7(d) of the Purchase Agreement. A new Section 7(d) of the Purchase Agreement is hereby
amended to read in its entirety as follows:

 

“(d)       On May
__, 2020, or such other date as mutually agreed by Buyer and the Company, the Buyer shall purchase 187,500 Fourth Closing Shares.
Such purchase and sale is subject to the satisfaction, at or before the Fourth Closing Date, of each of the following conditions,
provided that these conditions are for the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion
by providing the Company with prior written notice thereof:

 

(i)       The
Company shall have delivered to the Buyer a copy of the Irrevocable Transfer Agent Instructions with respect to the Fourth Closing,
which instructions shall have been delivered to and acknowledged in writing by the Company’s transfer agent.

 

(ii)       The
Company shall have duly executed and delivered to the Buyer (A) each of the Transaction Documents, (B) the Common Shares being
purchased by the Buyer at the Fourth Closing pursuant to this Agreement and (C) the related Warrants being purchased by the Buyer
at the Fourth Closing pursuant to this Agreement.

 

(iii)       The
representations and warranties of the Company contained in this Agreement shall be true and correct as of the date when made and
as of the Fourth Closing Date as though made at that time (except for representations and warranties that speak as of a specific
date which shall be true and correct as of such specified date) and the Company shall have performed, satisfied and complied in
all respects with the covenants, agreements and conditions required by the Transaction Documents to be performed, satisfied or
complied with by the Company at or prior to the Fourth Closing Date.

 

(iv)       The
Common Stock (I) shall be designated for quotation or listed on the Principal Market and (II) shall not have been suspended, as
of the Fourth Closing Date, by the SEC or the Principal Market from trading on the Principal Market nor shall suspension by the
SEC or the Principal Market have been threatened, as of the Fourth Closing Date, either (A) in writing by the SEC or the Principal
Market or (B) by falling below the minimum listing maintenance requirements of the Principal Market.

 

(v)       The
Company shall have obtained all governmental, regulatory or third party consents and approvals, if any, necessary for the sale
of the Securities.

 

(vi)       The
Company shall have delivered to the Buyer such other documents relating to the transactions contemplated by this Agreement as the
Buyer or its counsel may reasonably request.”

 

4.               
Amendment to Recitals. The recitals to the Purchase Agreement are hereby deemed to be amended to reflect the
amendments set forth in this Amendment as well as any prior amendment to the Purchase Agreement.

 

5.               
Representations and Warranties of the Company. The Company has the requisite corporate power and authority
to enter into and perform its obligations under this Amendment, including the Purchase Agreement as amended by this Amendment.
The execution and delivery of this Amendment and the consummation by the Company of the transactions contemplated hereby (including
the Purchase Agreement as amended by this Amendment), including, without limitation, the issuance of the Common Shares and the
Warrants and the reservation for issuance and the issuance of the Warrant Shares issuable upon exercise of the Warrants have been
duly authorized by the Company’s Board of Directors and no further filing, consent or authorization is required by the Company,
its Board of Directors or its stockholders. This Amendment has been duly executed and delivered by the Company, and constitutes
the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with its terms, except as
such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency, reorganization, moratorium,
liquidation or similar laws relating to, or affecting generally, the enforcement of applicable creditors’ rights and remedies

 

6.               
Miscellaneous.

 

(a)             
This Amendment shall be automatically effective upon the execution and delivery hereof by the Company and the Buyer.

 

(b)            
Except as expressly set forth herein, the Purchase Agreement shall remain in full force and effect.

 

 

 

    	 	2	 

     

    

 

(c)             
All questions concerning the construction, validity, enforcement and interpretation of this Amendment shall be governed
by the internal laws of the State of New York, without giving effect to any choice of law or conflict of law provision or rule
(whether of the State of New York or any other jurisdictions) that would cause the application of the laws of any jurisdictions
other than the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal
courts sitting in The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any
suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit,
action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper. Each
party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof to such party at the address for such notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in
any way any right to serve process in any manner permitted by law. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE,
AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR ARISING OUT OF THIS
AMENDMENT OR ANY TRANSACTION CONTEMPLATED HEREBY.

 

(d)            
This Amendment may be executed in counterparts, each of which shall be deemed an original, but both of which together shall
constitute one and the same instrument. Either or both parties may execute this Amendment by facsimile signature or scanned signature
in PDF format, and any such facsimile signature or scanned signature, if identified, legible and complete, shall be deemed an original
signature and each of the parties is hereby authorized to rely thereon.

 

(e)             
In the event one or more of the provisions of this Amendment should, for any reason, be held to be invalid, illegal or unenforceable
in any respect, such invalidity, illegality or unenforceability shall not affect any other provisions of this Amendment, and this
Amendment shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein. In the event
of any inconsistencies between this Amendment and the Purchase Agreement, the terms of this Amendment shall govern. Except as set
forth above, the Purchase Agreement shall remain in full force and effect in accordance with its terms.

 

(f)             
The provisions hereof shall inure to the benefit of, and be binding upon, the parties hereto and their respective successors,
assigns, heirs, executors and administrators and other legal representatives.

 

[Signature Pages Follow]

 

 

 

    	 	3	 

     

    

 

In
Witness Whereof, the parties hereto have executed this Amendment as of the date set forth in the first paragraph above.

 

COMPANY: 

 

Medicine
Man Technologies, Inc.

 

By:/s/ Nancy Huber               

       Name: Nancy Huber

       Title: Chief Financial Officer

 

 

 

 

[Amendment
to Securities Purchase Agreement]

 

    	 	4	 

     

    

 

 

In
Witness Whereof, the parties hereto have executed this Amendment as of the date set forth in the first paragraph above.

 

PURCHASER: 

 

Dye
Capital Cann Holdings, LLC

 

By: Dye Capital & Company, LLC, its

managing member

 

By:/s/ Justin Dye                 

       Name: Justin Dye

       Title: Managing Member

 

 

 

 

 

 

 

 

    	 	5fzmd-ex101_78.htm

EXHIBIT 10.1

Execution Version

 

 

LIMITED WAIVER AND FIFTH AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT

 

This LIMITED WAIVER AND FIFTH AMENDMENT TO AMENDED AND RESTATED

BUSINESS LOAN AGREEMENT (this “Amendment”), dated May 21, 2020 (the “Fifth Amendment Effective Date”), is made and entered into by and among Zions Bancorporation, N.A. dba Amegy Bank (together with its successors and assigns, “Lender”), Fuse Medical, Inc. (“Fuse”) and CPM Medical Consultants, LLC (“CPM”, together with Fuse, collectively, the “Borrowers” and each a “Borrower”).

 

RECITALS

 

	
A.
	
Lender and Borrowers are parties to that certain Amended and Restated Business Loan Agreement dated as of December 31, 2017 (as amended by that certain Limited Wavier and First Amendment to Amended and Restated Business Loan Agreement, dated as of September 21, 2018, as amended by that certain Limited Waiver and Second Amendment to Amended and Restated Business Loan Agreement, dated as of November 19, 2018, as amended by that certain Limited Waiver and Third Amendment to Amended and Restated Business Loan Agreement dated as of May 9, 2019, as amended by that certain Limited Waiver and Fourth Amendment to Amended and Restated Business Loan Agreement dated December 18, 2019 and as may be further amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Loan Agreement”).
	
 

 

	
 
	
B.
	
An Event of Default has occurred and is continuing, under the Loan Agreement.

 

	
C.
	
Borrowers have requested that Lender waive such Event of Default, and amend the Loan Agreement.
	
 

 

	
D.
	
Lender is willing to waive such Event of Default, and amend the Loan Agreement on the terms and subject to the conditions set forth below.
	
 

 

NOW, THEREFORE, in consideration of the premises herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

 

ARTICLE I

Definitions

 

Section 1.1 Definitions. Capitalized terms used in this Amendment, to the extent not otherwise defined herein, shall have the same definitions assigned to such terms in the Loan Agreement, as amended hereby.

 

ARTICLE II

Limited Waiver

 

Section 2.1 Limited Waiver. An Event of Default has occurred and currently exists under the Loan Agreement as a result of Borrowers’ failure to maintain the Minimum EBITDA of $125,000 for the fiscal quarter ended March 31, 2020 as required by Section 9.1(b) of the Loan Agreement (the “Specified Default”). Borrowers represent and warrant that the Specified Default is the only Default or Event of Default that exists, or is anticipated to occur, under the Loan Agreement and the other Loan Documents as of the Fifth Amendment Effective Date. Subject to the satisfaction of the conditions precedent set forth in Section 4.1 hereof, Lender hereby waives the Specified Default. In no event shall such waiver be deemed to constitute a waiver of (a) any Default or Event of Default other than the Specified Default or (b)

 

-1-

SMRH:4841-2483-8588.4
 

Borrowers’ obligation to comply with all of the terms and conditions of the Loan Agreement and the other Loan Documents from and after the Fifth Amendment Effective Date. Notwithstanding any prior, temporary mutual disregard of the terms of any contracts between the parties, Borrowers hereby agree that they shall be required strictly to comply with all of the terms of the Loan Documents on and after the Fifth Amendment Effective Date.

 

ARTICLE III

 

Amendments to the Loan Agreement

 

In reliance upon the representations and warranties of the Lender and Borrowers set forth in the Loan Documents and in this Amendment, the Loan Agreement is hereby amended, effective as of the Fifth Amendment Effective Date, as follows:

 

Section 3.1Amendments.

 

	
(a)
	
The following definitions in Section 1.1 of the Loan Agreement are hereby amended and restated in their entirety as follows:
	
 

 

“Permitted Debt” means (a) Debt constituting purchase money indebtedness or Capital Lease Obligations in an aggregate amount outstanding not to exceed

$250,000, (b) the Obligations, (c) trade payables and other contractual obligations arising in the ordinary course of business that are not past due by more than 90 days, (d) the Earn-Out so long as it is subject to the Earn-Out Subordination Agreement, (e) Debt existing on the Closing Date and described on Schedule 10.3 attached hereto and made a part hereof, (f) the Subordinated Debt and (g) the PPP Debt.

 

“Termination Date” means the earliest to occur of (a) November 4, 2020 and (b) the date on which Lender’s commitment to make Loans is terminated pursuant to Section 10.2.

 

	
(b)
	
Section 1.1 of the Loan Agreement is hereby amended to insert therein in appropriate alphabetical order the following defined terms:
	
 

 

“CARES Act – Title I” means Title I of the Coronavirus Aid, Relief and Economic Security Act, as amended (including any successor thereto), and all requests, rules, guidelines, requirements and directives thereunder or issued in connection therewith or in implementation thereof, regardless of the date enacted, adopted, issued or implemented.

 

“NC 143” means NC 143 Family Holding, LP, a Texas limited partnership.

 

“NC 143 Debt” means the indebtedness evidenced by the NC 143 Note in a maximum amount not exceeding the amount thereof permitted by the NC 143 Subordination Agreement.

 

“NC 143 Loan Proceeds” means the proceeds of the loan evidenced by the NC 143 Promissory Note, the amount of which shall be no less than $180,000.

 

“NC 143 Note” means that certain Promissory Note dated May 6, 2020, by Fuse in favor of NC 143, in the original principal amount of $180,000.

 

-2-

SMRH:4841-2483-8588.4
 

“NC 143 Subordination Agreement” means that certain Subordination Agreement dated May 20, 2020, by and among Lender, NC 143 and Borrowers.

 

“PPP Debt” means unsecured Debt of CPM to Zions Bancorporation, N.A. dba Amegy Bank in an aggregate principal amount not to exceed $361,400 advanced by any governmental authority (including the Small Business Administration) or any other Person acting as a financial agent of a governmental authority or any other Person to the extent such Debt is guaranteed by a governmental authority (including the Small Business Administration), in each case pursuant to the CARES Act – Title I.

 

“Reeg” means Reeg Medical Industries, Inc., a Texas corporation.

 

“Reeg Debt” means the indebtedness evidenced by the Reeg Note in a maximum amount not exceeding the amount thereof permitted by the Reeg Subordination Agreement.

 

“Reeg Loan Proceeds” means the proceeds of the loan evidenced by the Reeg Promissory Note, the amount of which shall be no less than $20,000.

 

“Reeg Note” means that certain Promissory Note dated May 6, 2020, by Fuse in favor of Reeg, in the original principal amount of $20,000.

 

“Reeg Subordination Agreement” means that certain Subordination Agreement dated May 20, 2020, by and among Lender, Reeg and Borrowers.

 

“Subordinated Loan Proceeds” means, collectively, the NC 143 Loan Proceeds and the Reeg Loan Proceeds.

 

“Subordinated Debt” mean, collectively, the NC 143 Debt and the Reeg Debt.

 

“Subordinated Debt Documents” means, collectively, the Subordinated Notes and the Subordination Agreements.

 

“Subordinated Notes” means, collectively, the NC 143 Note and the Reeg Note.

 

“Subordination Agreements” means, collectively, the NC 143 Subordination Agreement and the Reeg Subordination Agreement.

 

	
(b)
	
Section 9.1(b) of the Loan Agreement is hereby amended and restated to read in its entirety as follows:
	
 

 

“(b)Minimum EBITDA. Borrowers shall not permit EBITDA for the two (2) fiscal quarter period ending September 30, 2020 to be less than $25,000.”

 

	
(c)
	
Section 10.1 of the Loan Agreement is hereby amended by (i) replacing the “.” at the end of subsection 10.1(q) with “;”, (ii) replacing the “.” at the end of subsection 10.1(r) with “; or” and (iii) adding a new subsection 10.1(s) immediately after subsection 10.1(r), which new subsection 10.1(s) shall read in its entirety as follows:
	
 

 

-3-

SMRH:4841-2483-8588.4
 

“(s)  The subordination provisions related to any Subordinated Debt shall for   any reason be revoked or invalidated, or otherwise cease to be in full force and effect, or any Person shall contest in any manner the validity or enforceability thereof or deny that it has any further liability or obligation thereunder, or the Obligations under the Loan Documents for any reason shall not have the priority contemplated by this Agreement or any such subordination provisions.”

 

ARTICLE IV

Conditions Precedent

 

Section 4.1 Conditions Precedent. The effectiveness of this Amendment is subject to the satisfaction of the following conditions precedent, unless specifically waived in writing by Lender, upon which this Amendment shall be effective as of the Fifth Amendment Effective Date:

 

(a)Lender shall have received a counterpart of this Amendment duly executed by Borrowers and the Consent and Reaffirmation duly executed by Guarantors;

 

(b)the representations and warranties contained herein and in all other Loan Documents shall be true and correct as of the Fifth Amendment Effective Date as if made on the Fifth Amendment Effective Date;

 

(c)no Default or Event of Default shall have occurred and be continuing other than the Specified Default;

 

(d)Borrowers shall have paid all reasonable costs and expenses incurred by Lender in connection with the preparation, negotiation and execution of this Amendment and the other Loan Documents executed pursuant hereto, including, without limitation, the costs and fees of Lender’s legal counsel and such counsel’s outstanding invoices related to the preparation of the Loan Documents and amendments thereto;

 

(e)Fuse shall have received the Subordinated Loan Proceeds in an aggregate amount no less than $200,000; and

 

(f)Lender shall have received duly executed copies of each of the Subordinated Debt Documents in form and substance satisfactory to Lender.

 

ARTICLE V

Ratifications, Representations, Warranties, Acknowledgments and Covenants

 

Section 5.1 Ratifications by Borrowers. The terms and provisions set forth in this Amendment shall modify and supersede all inconsistent terms and provisions set forth in the Loan Agreement and, except as expressly modified and superseded by this Amendment, the terms and provisions of the Loan Agreement are ratified and confirmed and shall continue in full force and effect. The Loan Agreement as amended by this Amendment shall continue to be legal, valid, binding and enforceable in accordance with its terms.

 

Section 5.2        Renewal and Extension of Security Interests and Liens.  Each Borrower hereby

(a) renews and affirms the Liens created and granted in the Loan Documents, and (b) agrees that this Amendment shall in no manner affect or impair the Liens securing the Obligations, and that such Liens shall not in any manner be waived, the purposes of this Amendment being to modify the Loan Agreement

 

-4-

SMRH:4841-2483-8588.4
 

as herein provided, and to carry forward all Liens securing the same, which are acknowledged by such Borrower to be valid and subsisting.

 

Section 5.3 Representations and Warranties. Each Borrower represents and warrants to Lender that (a) the execution, delivery and performance of this Amendment and any and all Loan Documents executed and/or delivered in connection herewith have been authorized by all requisite entity action on the part of such Borrower and will not violate the organizational documents of such Borrower or any agreement to which such Borrower is a party, (b) the representations and warranties contained in the Loan Agreement and in each of the other Loan Documents are true and correct on and as of the Fifth Amendment Effective Date as though made on the Fifth Amendment Effective Date, (c) no Default or Event of Default under the Loan Agreement has occurred and is continuing other than the Specified Default, and (d) such Borrower is in full compliance with all covenants and agreements contained in the Loan Agreement, as amended hereby.

 

ARTICLE VI

Miscellaneous

 

Section 6.1  Survival of Representations and Warranties.  All representations and warranties  made in the Loan Agreement or any other Loan Document, including without limitation, any Loan Document furnished in connection with this Amendment, shall survive the execution and delivery of this Amendment and the other Loan Documents, and no investigation by Lender or any closing shall affect such representations and warranties or the right of Lender to rely thereon.

 

Section 6.2 Reference to Loan Agreement. Each of the Loan Documents and any and all other agreements, documents or instruments now or hereafter executed and delivered pursuant to the terms hereof or pursuant to the terms of the Loan Agreement as amended hereby, are hereby amended so that any reference in such Loan Documents to the Loan Agreement shall mean a reference to the Loan Agreement as amended hereby.

 

Section 6.3 Expenses of Lender. Borrowers agree to pay on demand all reasonable costs and expenses incurred by Lender directly in connection with any and all amendments, modifications, and supplements to this Amendment and the other Loan Documents executed pursuant hereto, including, without limitation, the costs and fees of Lender’s legal counsel, and all costs and expenses incurred by Lender in connection with the enforcement or preservation of any rights under the Loan Agreement, as amended hereby, or any other Loan Document, including, without limitation, the reasonable costs and fees of Lender’s legal counsel.

 

Section 6.4 Severability. Any provision of this Amendment held by a court of competent jurisdiction to be invalid or unenforceable shall not impair or invalidate the remainder of this Amendment and the effect thereof shall be confined to the provision so held to be invalid or unenforceable.

 

Section 6.5 APPLICABLE LAW. THIS AMENDMENT SHALL BE DEEMED TO HAVE BEEN MADE AND TO BE PERFORMABLE IN AND SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS NOT INCLUDING CONFLICTS OF LAW RULES.

 

Section 6.6 WAIVER OF JURY TRIAL. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE PARTIES HERETO EACH HEREBY WAIVES THE RIGHT TO TRIAL BY JURY IN ANY ACTION, SUIT, COUNTERCLAIM, OR PROCEEDING ARISING OUT OF OR RELATED TO THIS AMENDMENT.

 

-5-

SMRH:4841-2483-8588.4
 

Section 6.7 RELEASE OF CLAIMS. TO INDUCE LENDER TO ENTER INTO THIS AMENDMENT, EACH BORROWER, AND BY GUARANTORS’ SIGNATURES TO THE CONSENT AND REAFFIRMATION, EACH GUARANTOR VOLUNTARILY, KNOWINGLY AND UNCONDITIONALLY RELEASES, ACQUITS, AND FOREVER DISCHARGES LENDER AND ITS OFFICERS, DIRECTORS, AGENTS, EMPLOYEES, SUCCESSORS, AND ASSIGNS (COLLECTIVELY, THE “RELEASED PARTIES”), FROM ANY AND ALL LIABILITIES, CLAIMS, DEMANDS, DAMAGES, EXPENSES, ACTIONS, OR CAUSES OF ACTION OF ANY KIND OR NATURE (IF THERE BE ANY), WHETHER ABSOLUTE OR CONTINGENT, DISPUTED OR UNDISPUTED, AT LAW OR IN EQUITY, OR KNOWN OR UNKNOWN, THAT SUCH BORROWER NOW HAS OR EVER HAD AGAINST ANY OF THE RELEASED PARTIES ARISING UNDER OR IN CONNECTION WITH ANY OF THE LOAN DOCUMENTS OR OTHERWISE, INCLUDING, WITHOUT LIMITATION, ANY SUCH LIABILITIES, CLAIMS, DEMANDS, DAMAGES, EXPENSES, ACTIONS, OR CAUSES OF ACTION ARISING OUT OF OR RELATING TO A CLAIM OF BREACH OF CONTRACT, FRAUD, LENDER LIABILITY OR MISCONDUCT, BREACH OF FIDUCIARY DUTY, USURY, UNFAIR BARGAINING POSITION, UNCONSCIONABILITY, VIOLATION OF LAW, NEGLIGENCE, ERROR OR OMISSION IN ACCOUNTING OR CALCULATIONS, MISAPPROPRIATION OF FUNDS, TORTIOUS CONDUCT OR RECKLESS OR WILLFUL MISCONDUCT. EACH BORROWER AND EACH GUARANTOR REPRESENTS AND WARRANTS TO LENDER THAT IT HAS NOT TRANSFERRED OR ASSIGNED TO ANY PERSON ANY CLAIM THAT IT HAS EVER HAD OR CLAIMED TO HAVE AGAINST ANY RELEASED PARTY.

 

Section 6.8 Successors and Assigns. This Amendment is binding upon and shall inure to the benefit of the parties hereto and their respective successors, assigns, heirs, executors, and legal representatives, except that none of the parties hereto other than Lender may assign or transfer any of its rights or obligations hereunder without the prior written consent of Lender.

 

Section 6.9  Counterparts.  This  Amendment may  be  executed in one  or more counterparts, each of which when so executed shall be deemed to be an original, but all of which when taken together shall constitute one and the same instrument. Any signature delivered by a party by facsimile or other electronic transmission shall be deemed to be an original signature hereto.

 

Section 6.10  Effect of Waiver.  No consent or waiver, express or implied, by Lender to or for  any breach of or deviation from any covenant, condition or duty by any Borrower, shall be deemed a consent to or waiver of any other breach of the same or any other covenant, condition or duty.

 

Section 6.11 Headings.  The headings, captions, and arrangements used in this Amendment are for convenience only and shall not affect the interpretation of this Amendment.

 

Section 6.12 Conflicting Provision. If any provision of the Loan Agreement as amended hereby conflicts with any provision of any other Loan Document, the provision in the Loan Agreement shall control.

 

Section 6.13 ENTIRE AGREEMENT.  THIS AMENDMENT, THE LOAN AGREEMENT  AND ALL OTHER LOAN DOCUMENTS EXECUTED AND DELIVERED IN CONNECTION WITH AND PURSUANT TO THIS AMENDMENT AND THE LOAN AGREEMENT REPRESENT THE FINAL AGREEMENT BETWEEN THE PARTIES AND MAY NOT BE CONTRADICTED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS, OR SUBSEQUENT ORAL AGREEMENTS OF THE PARTIES. THERE ARE NO UNWRITTEN ORAL AGREEMENTS BETWEEN THE PARTIES.

 

[Signature Pages Follow]

 

-6-

SMRH:4841-2483-8588.4
 

 

IN WITNESS WHEREOF, the parties hereto have caused this Limited Waiver and Fifth Amendment to be duly executed and delivered as of the date first written above.

 

 

BORROWER:

 

 

FUSE MEDICAL, INC

 

 

By: /s/ Christopher C. Reeg                       

Name: Christopher C. Reeg

Title: Chief Executive Officer

 

 

 

BORROWER:

 

CPM MEDICAL CONSULTANTS, LLC

 

 

By: /s/ Christopher C. Reeg                     

Name: Christopher C. Reeg

Title: Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURE PAGE TO LIMITED WANER AND FIFTII AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT

FUSE MEDICAL, INC. & CPM MEDICAL CONSULTANTS, LLC

 

(MAY2020)
 

 

 

LENDER:

 

ZIONS BANCORPORATION, N.A. dba AMEGY

BANK

 

 

By: /s/ Nicholas Diaz                              

Name: Nicholas Diaz

Title: Executive Vice President

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURE PAGE TO LIMITED WAIYER AND FIFTH AMENDMENT TO AMENDED AND RESTATED BUSINESS LOAN AGREEMENT FUSE MEDICAL, INC. & CPM MEDICAL CONSULTANTS, LLC

 

(MAY2020)
 

 

CONSENT AND REAFFIRMATION

 

 

Each of the undersigned guarantors acknowledges that Zions Bancorporation, N.A. dba Amegy Bank) ("Lender'') has no obligation to provide it with notice of, or to obtain its consent to, the terms of the foregoing Limited Waiver and Fifth Amendment to the Amended and Restated Business Loan Agreement (the "Amendment") . Nevertheless, each of the undersigned consents to the Amendment and other Loan Documents effected thereby, agrees to be bound thereby and confirms and agrees that, notwithstanding the effectiveness of the Amendment, each Loan Document to which the undersigned is a party is, and the obligations thereunder to which it is a party are, and shall continue to be, in full force and effect and are hereby ratified and confirmed in all respects, in each case as amended by the Amendment.

 

 

GUARANTORS:

 

NC 143 FAMILY HOLDINGS LP

 

	
 
	
By:
	
NC 143 Family Holdings GP LLC, General Partner of NC 143 Family Holdings LP
	
 

 

	
 
	
By:
	
NC 143 Family Trust, Dated October 1, 2014, as last amended, Manager of NC 143 Family Holdings GP LLC
	
 

 

 

 

By: /s/ Mark W. Brooks                  

Name: Mark W. Brooks

Title: Trustee of NC 143 Family Trust

 

 

By: /s/ Penelope A. Brooks             

Name: Penelope A. Brooks

Title: Trustee of NC 143 Family Trust

 

 

MARK W. BROOKS

By: /s/ Mark W. Brooks               

 

 

 

 

 

 

 

 

 

 

 

S IG NAT URH PAGE TO LIMITED WAIVER AND FIFTH AMHNDMENT TO AMHNDED AND RB STATED B USINHSS LOAN AGRHEMENT

FUSE MEDICAL, INC. & CPM MEDICAL CONSULTANTS, LLC

(MAY2020)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00309-of-00352.parquet"}]]